`Date filed: October 31, 2014
`
`Filed On Behalf Of:
`
`Novartis AG and LTS Lohmann Therapie-Systeme AG
`
`By:
`
`Raymond R. Mandra
`ExelonPatchIPR@fchs.com
`(212) 218-2100
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`NOVEN PHARMACEUTICALS INC.,
`Petitioner
`
`v.
`
`NOVARTIS AG AND LTS LOHMANN THERAPIE-SYSTEME AG,
`Patent Owners
`
`Inter Partes Review No. 2014-00549
`
`U.S. Patent 6,316,023
`
`PATENT OWNERS’ UPDATED MANDATORY NOTICES
`UNDER 37 C.F.R. § 42.8(a)(3)
`
`
`
`Pursuant to 37 C.F.R. § 42.8(a)(3), the following updated mandatory notices
`
`are being filed with the Patent Trial and Appeal Board (“Board”).
`
`REAL PARTY-IN-INTEREST
`
`The real party-in-interest information has not changed.
`
`RELATED MATTERS
`
`The Patent Owners hereby notify the Board of changes in the related matters
`
`in the present proceedings pursuant to 37 C.F.R. § 42.8(b)(2).
`
`U.S. Patent 6,316,023 is being asserted in the following patent infringement
`
`lawsuits: (1) Novartis Pharm. Corp. et al. v. Par Pharm. Inc. et al., 1:11-cv-01077
`
`(D. Del.); (2) Novartis Pharm. Corp. et al. v. Watson Labs. Inc. et al., 1:11-cv-
`
`01112 (D. Del.); (3) Novartis Pharm. Corp. et al. v. Actavis, Inc. et al., 1:13-cv-
`
`00371 (D. Del.); (4) Novartis Pharm. Corp. et al. v. Noven Pharm. Inc. et al., 1:13-
`
`cv-00527 (D. Del.); (5) Novartis Pharm. Corp. et al. v. Noven Pharm. Inc., 1:14-
`
`cv-00111 (D. Del.); (6) Novartis Pharm. Corp. et al. v. Mylan Inc. et al., 1:14-cv-
`
`00777 (D. Del.); (7) Novartis Pharm. Corp. et al. v. Mylan Inc. et al., 1:14-cv-
`
`00106 (N.D.W.V.); (8) Novartis Pharm. Corp. et al. v. Zydus Noveltech Inc. et al.,
`
`1:14-cv-01104 (D. Del.); (9) Novartis Pharm. Corp. et al. v. Zydus Noveltech Inc.
`
`et al., 1:14-cv-05405 (D.N.J.); (10) Watson Labs. Inc. et al. v. Novartis Pharm.
`
`Corp. et al., 14-1799 (C.A.F.C.); (11) Novartis Pharm. Corp. et al. v. Par Pharm.
`
`1
`
`
`
`Inc. et al., 15-1061 (C.A.F.C.); and (12) Par Pharm. Inc. v. Novartis Pharm. Corp.
`
`et al., 15-1120 (C.A.F.C.).
`
`LEAD AND BACK-UP COUNSEL
`
`The lead and back-up counsel information has not changed.
`
`SERVICE INFORMATION
`
`The service information has not changed.
`
`POWER OF ATTORNEY
`
`The power of attorney information has not changed.
`
`Respectfully submitted,
`
`Dated: October 31, 2014
`
`/Raymond R. Mandra/
`Raymond R. Mandra
`Registration No. 34,382
`Lead Counsel for Patent Owners
`FITZPATRICK, CELLA, HARPER
`& SCINTO
`1290 Avenue of the Americas
`New York, NY 10104-3800
`Tel. 212-218-2100
`
`2
`
`
`
`CERTIFICATE OF SERVICE
`
`I certify that a copy of the Patent Owners’ Updated Mandatory Notices
`
`Under 37 C.F.R. § 42.8(a)(3) was served on October 31, 2014 by causing it to be
`
`sent by email to counsel for Petitioner at the following email addresses:
`
`Steven J. Lee (slee@kenyon.com)
`
`Michael K. Levy (mlevy@kenyon.com)
`
`Dated: October 31, 2014
`
`/Raymond R. Mandra/
`Raymond R. Mandra
`Registration No. 34,382
`FITZPATRICK, CELLA, HARPER
`& SCINTO
`1290 Avenue of the Americas
`New York, NY 10104-3800
`Tel. 212-218-2100
`
`3